Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon
Thumbnail

Top medical groups release new appropriate use criteria for PSMA-PET imaging

SNMMI is among the many organizations that collaborated on the updated guidance for imaging prostate cancer.

District of Columbia DC congress capitol hill

Lawmakers request records from FDA on Alzheimer’s drug approval, citing ‘apparent anomalies’

Part of their list includes info regarding the agency's move to approve Aduhelm for broader treatment indications than studied during clinical testing, a gripe similar to complaints cited by SNMMI.

Thumbnail

Transformative prostate cancer therapy ‘should not be accepted’ without PET imaging

Two Stanford University experts made their case for using molecular imaging to select patients for 177-Lu-PSMA-617 in a new Journal of Nuclear Medicine editorial.

Thumbnail

As regulators weigh revising nuclear medicine reporting rules, imaging advocates and others take sides

Researchers say extravasations should be more closely monitored and reported, while the ACR and SNMMI caution these events are rare and don't require intense scrutiny.

Medical isotope specialist NorthStar announces new executive hire

Frank Scholz, PhD, will oversee the Beloit, Wisconsin, firm's Mo-99 expansion efforts and new radioisotope development programs, among other duties.

Thumbnail

Combining AI with cardiac imaging helps predict heart attacks, cardiovascular deaths

The findings were presented virtually during the Society of Nuclear Medicine and Molecular Imaging's 2021 Annual Meeting.

Thumbnail

Imaging advocates offer guidance after reported spate of SPECT/CT payment denials

The Society of Nuclear Medicine & Molecular Imaging said it’s received “many complaints” from the field pertaining to various commercial payers. 

‘Partial victory’: Imaging advocates say Humana relenting on some PET/CT payment restrictions

The health insurer reversed its coverage denial for imaging of gastric and esophageal oncologic indications, while other restrictions remain in place. 

Displaying 185 - 192 of 225

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.